Highlights from the EHA Conference - Chronic Lymphocytic Leukaemia (CLL)

Highlights from the EHA Conference - Chronic Lymphocytic Leukaemia (CLL)

CLL highlights from EHA and ICML: the CLL-12 studyПодробнее

CLL highlights from EHA and ICML: the CLL-12 study

EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALLПодробнее

EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALL

EHA 2023 CLL highlightsПодробнее

EHA 2023 CLL highlights

Highlights from the ERIC International MeetingПодробнее

Highlights from the ERIC International Meeting

EHA 2020 CLL highlights: CLL14 & CAPTIVATEПодробнее

EHA 2020 CLL highlights: CLL14 & CAPTIVATE

What can delegates look forward to this week at EHA 2020?Подробнее

What can delegates look forward to this week at EHA 2020?

Highlights from the EHA Conference - Chronic Myeloid Leukaemia (CML)Подробнее

Highlights from the EHA Conference - Chronic Myeloid Leukaemia (CML)

Highlights from the EHA Conference - Acute Lymphoblastic Leukaemia (ALL)Подробнее

Highlights from the EHA Conference - Acute Lymphoblastic Leukaemia (ALL)

Highlights from the European Haematology Association Conference - Acute Myeloid Leukaemia (AML)Подробнее

Highlights from the European Haematology Association Conference - Acute Myeloid Leukaemia (AML)

Highlights of the European Haematology Association (EHA) ConferenceПодробнее

Highlights of the European Haematology Association (EHA) Conference

Highlights from EHA 2016 press briefings: Nivolumab, SGN-CD33A and hemophiliaПодробнее

Highlights from EHA 2016 press briefings: Nivolumab, SGN-CD33A and hemophilia

2014 EHA Congress HighlightsПодробнее

2014 EHA Congress Highlights

Understanding ultra high-risk CLL and advances with IbrutinibПодробнее

Understanding ultra high-risk CLL and advances with Ibrutinib

Новости